Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases

Experimental Cell Research

Volumn 312, Issue 19, 2006, Pages 3892-3898

  Shin, Jin Na ^a   Park, Sun Young ^a   Cha, Jong Hee ^a   Park, Jae Yoon ^a   Lee, Byung Rai ^a   Jung, Sun Ah ^b   Lee, Seung Taek ^b   Yun, Cheol Won ^c   Seol, Dai Wu ^d   Kim, Tae Hyoung ^a  

^a Chosun University   (South Korea)

^b Yonsei University   (South Korea)

^c Korea University   (South Korea)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell death; Matrix metalloproteinase; TRAIL

Indexed keywords

INTERLEUKIN 18; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL ACTIVITY; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS;

EID: 33750366469     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.08.015     Document Type: Article

References (34)

1. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 (1996) 12687-12690
2. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
3. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10 (2003) 66-75
4. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
5. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16 (2002) 33-45
6. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., Fong S., Schwall R., Sinicropi D., and Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8 (2002) 274-281
7. Ravi R., and Bedi A. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res. 62 (2002) 1583-1587
8. Griffith T.S., and Lynch D.H. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10 (1998) 559-563
9. Ashkenazi A., and Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11 (1999) 255-260
10. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
11. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., and Strom S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6 (2000) 564-567
12. Matysiak M., Jurewicz A., Jaskolski D., and Selmaj K. TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 125 (2002) 2469-2480
13. Nitsch R., Bechmann I., Deisz R.A., Haas D., Lehmann T.N., Wendling U., and Zipp F. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356 (2000) 827-828
14. Mott J.D., and Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16 (2004) 558-564
15. Vu T.H., and Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14 (2000) 2123-2133
16. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 253 (2003) 269-285
17. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev., Cancer 2 (2002) 161-174
18. Shin J.N., Seo Y.W., Kim M., Park S.Y., Lee M.J., Lee B.R., Oh J.W., Seol D.W., and Kim T.H. Cisplatin inactivation of caspases inhibits death ligand-induced cell death in vitro and fulminant liver damage in mice. J. Biol. Chem. 280 (2005) 10509-10515
19. Jo Y., Yoon D.W., Kim M.Y., Lee Y.J., Kim H.J., and Lee S.T. J. Biochem. Mol. Biol. 32 (1999) 60-66
20. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., and Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264 (1989) 17213-17221
21. Rosenberg G.A., Estrada E.Y., Dencoff J.E., and Stetler-Stevenson W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 703 (1995) 151-155
22. Ries C., Kolb H., and Petrides P.E. Regulation of 92-kD gelatinase release in HL-60 leukemia cells: tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion. Blood 83 (1994) 3638-3646
23. Migita K., Eguchi K., Kawabe Y., Ichinose Y., Tsukada T., Aoyagi T., Nakamura H., and Nagataki S. TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts. Immunology 89 (1996) 553-557
24. Kondo T., Suda T., Fukuyama H., Adachi M., and Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3 (1997) 409-413
25. Leist M., Gantner F., Bohlinger I., Tiegs G., Germann P.G., and Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146 (1995) 1220-1234
26. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W., Krammer P.H., and Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182 (1995) 1223-1230
27. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J., and Fox J.A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299 (2001) 31-38
28. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., and Anderson K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 (2001) 795-804
29. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest 104 (1999) 155-162
30. Ortega N., Behonick D.J., and Werb Z. Matrix remodeling during endochondrial ossification. Trends Cell Biol. 14 (2004) 86-93
31. Moran A., Iniesta P., Garcia-Aranda C., De Juan C., Diaz-Lopez A., Sanchez-Pernaute A., Torres A.J., Diaz-Rubio E., Balibrea J.L., and Benito M. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol. Rep. 13 (2005) 115-120
32. Trudel D., Fradet Y., Meyer F., Harel F., and Tetu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 63 (2003) 8511-8515
33. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev., Cancer 2 (2002) 657-672
34. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516